← Back to Search

Monoclonal Antibody

JSP191 for MDS/AML

Phase 1
Waitlist Available
Led By Lori Muffly, MD,MS
Research Sponsored by Jasper Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year post donor cell transplant (28 days dose limiting toxicity period)
Awards & highlights

Study Summary

This trial is testing a new antibody conditioning regimen to see if it is safe and tolerable for people with Myelodysplastic Syndrome or Acute Myeloid Leukemia who are undergoing allogenic blood stem cell transplantation.

Eligible Conditions
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year post donor cell transplant (28 days dose limiting toxicity period)
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year post donor cell transplant (28 days dose limiting toxicity period) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The number of dose limiting toxicities will be assessed.
The number of subjects experiencing adverse events and serious adverse events will be assessed.
The type of dose limiting toxicities will be assessed.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Blood Stem Cell Transplant w/ anti-CD117 conditioningExperimental Treatment1 Intervention
The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery. The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose.

Find a Location

Who is running the clinical trial?

Jasper Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
114 Total Patients Enrolled
Lori Muffly, MD,MSPrincipal InvestigatorStanford University
Andrew Artz, MD,MSPrincipal InvestigatorCity of Hope Medical Center

Media Library

JSP191 (Monoclonal Antibody) Clinical Trial Eligibility Overview. Trial Name: NCT04429191 — Phase 1
Myelodysplastic Syndrome Research Study Groups: Blood Stem Cell Transplant w/ anti-CD117 conditioning
Myelodysplastic Syndrome Clinical Trial 2023: JSP191 Highlights & Side Effects. Trial Name: NCT04429191 — Phase 1
JSP191 (Monoclonal Antibody) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04429191 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Humanized anti-CD117 Monoclonal Antibody (JSP191) been granted regulatory authorization by the FDA?

"The safety of Humanized Anti-CD117 Monoclonal Antibody (JSP191) is rated as a 1 due to the preliminary nature of Phase 1 trials, in which there is little data available on efficacy and safety."

Answered by AI

What is the geographical spread of this trial's implementation?

"At the moment, 6 clinical sites are running this trial. Apart from Portland, Stanford and Salt Lake City there is another trio of locations available to choose from. It's important that participants select a nearby site in order to minimize their traveling duties should they participate."

Answered by AI

What is the enrollment rate of this research project?

"Affirmative. According to the information hosted on clinicaltrials.gov, this study is currently recruiting participants after its initial posting date of July 8th 2020 and subsequent revision on June 8th 2021. The trial hopes to register 40 patients from 6 different sites."

Answered by AI

Are there any available slots in this research project?

"Affirmative. As per the information on clinicaltrials.gov, this clinical trial is actively searching for patients to enroll in their research; it was initially posted on July 8th 2020 and edited most recently on June 8th 2021. Participants are needed from 6 distinct medical sites with a total of 40 required overall."

Answered by AI
~8 spots leftby Apr 2025